Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,498 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Terminated Phase 3 Interventional Results available

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

NCT05418673
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIIB122, BIIB122-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
30 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.

NCT02088073
View directory record Official record
Conditions
Hyperkalemia
Interventions
Sodium zirconium cyclosilicate, Placebo
Drug
Lead sponsor
ZS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsboro, Alabama + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function

NCT01678794
View directory record Official record
Conditions
Cardiorenal Syndrome (CRS)
Interventions
Candesartan, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

NCT00116805
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TDF, ADV, TDF placebo, ADV placebo, FTC/TDF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
20
States / cities
Orange, California • Pasadena, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure

NCT02497937
View directory record Official record
Conditions
Heart Failure
Interventions
GSK2798745, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 17, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis

NCT04130919
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tilpisertib, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
23
States / cities
Dothan, Alabama • Lancaster, California • Murrieta, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus

NCT02453711
View directory record Official record
Conditions
Metabolism and Nutrition Disorder, Obesity
Interventions
semaglutide, liraglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Anaheim, California • San Diego, California • Golden, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1 Interventional Results available

Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

NCT04370873
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Frespaciguat, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
40 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Lexington, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Effect of Febuxostat on Blood Pressure

NCT01496469
View directory record Official record
Conditions
Hypertension
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Foley, Alabama • Buena Park, California • Carmichael, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

NCT01318694
View directory record Official record
Conditions
Hepatitis C
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Beverly Hills, California • Oakland, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360529
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • South Birmingham, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

NCT04596631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
10 Years to 18 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily

NCT01089751
View directory record Official record
Conditions
Overactive Bladder
Interventions
trospium chloride, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

NCT02061202
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mometasone Furoate, Placebo
Drug
Lead sponsor
Jeffrey Glassberg
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Oct 17, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

NCT03980730
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Tucson, Arizona • New Haven, Connecticut • Atlantis, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

NCT00683800
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
desvenlafaxine succinate (DVS) SR, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
45 Years and older · Female only
Enrollment
2,186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932
View directory record Official record
Conditions
Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions
IV Ganciclovir, Placebo
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
14
States / cities
Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 17, 2026, 1:08 PM EDT
Terminated Phase 2 Interventional Results available

Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)

NCT03617263
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease in Women With PCOS
Interventions
Saroglitazar Magnesium 4 mg Tablet, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Chandler, Arizona • Panorama City, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 3 Interventional

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

NCT01968005
View directory record Official record
Conditions
Low Back Pain
Interventions
Etoreat®(Etodolac-Lidocaine Topical Patch), Placebo
Drug
Lead sponsor
MEDRx USA, Inc.
Industry
Eligibility
14 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Carlsbad, California • Miami, Florida • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Examine the Effects of Minocycline Extended-Release Tablets on Sperm Production in Human Males.

NCT00765336
View directory record Official record
Conditions
Human Volunteer
Interventions
minocycline extended release, Placebo
Drug
Lead sponsor
Medicis Pharmaceutical Corporation
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
10
States / cities
Tarzana, California • Minneapolis, Minnesota • Lawrenceville, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 2 Interventional Results available

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

NCT02258451
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Placebo (saline), Exemestane, Everolimus
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 17, 2026, 1:08 PM EDT
Completed Phase 1 Interventional

A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris

NCT06733402
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Trifarotene Cream 0.005%, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 17, 2026, 1:08 PM EDT
Recruiting Phase 3 Interventional

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

NCT06082037
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Belumosudil, Azithromycin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 17, 2026, 1:08 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Repeated CBD Administration and Cannabis Outcomes

NCT07434895
View directory record Official record
Conditions
Cannabis, Abuse Liability, Experimental Pain in Healthy Human Participants
Interventions
Cannabidiol, Medium Dose, Cannabidiol, Higher Dose, Active Inhaled Cannabis, Placebo Cannabidiol, Placebo Inhaled Cannabis
Drug
Lead sponsor
Hannah Harris
Other
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 17, 2026, 1:08 PM EDT